April 22nd 2024
Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Tailoring Treatment for High-Risk Bladder Cancer: Beyond BCG
February 2nd 2024In an interview with Targeted Oncology, Stephen Williams, MD, discussed a retrospective cohort study analyzing intravesical gemcitabine usage vs Bacillus Calmette-Guérin for the treatment of high-risk non-muscle invasive bladder cancer.
Read More
Enfortumab Vedotin/Pembrolizumab Outperforms Chemotherapy in mUC
January 30th 2024In an interview with Targeted Oncology, Thomas Powles, MD, MBBS, MRCP, discussed the impressive performance of enfortumab vedotin plus pembrolizumab for the treatment of locally advanced or metastatic urothelial carcinoma, as seen in the EV-302 trial.
Read More
Adjuvant Pembrolizumab Shows Clinically Significant DFS Benefit in Urothelial Carcinoma
January 27th 2024The phase 3 AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma successfully achieved its primary end point. However, the interim analysis did not meet the overall survival end point.
Read More
Enfortumab Vedotin With Pembrolizumab Shows Consistent OS Advantage in Urothelial Carcinoma
January 27th 2024The phase 3 EV-302/KEYNOTE-A39 trial, which includes prespecified subgroup analyses, revealed favorable outcomes compared with chemotherapy. The findings pertain to patients with previously untreated locally advanced or metastatic urothelial carcinoma.
Read More
Nadofaragene Firadenovec Continues to Demonstrate Durable Activity in NMIBC
January 17th 2024Three-year data showed durable clinical activity with nadofaragene firadenovec-vncg in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.
Read More
The End of Conventional Chemotherapy for Urothelial Cancer
December 21st 2023According to John M. Burke, MD, it is hard to imagine that results presented at ESMO in the urothelial cancer space will not lead to the complete replacement of conventional chemotherapy as the standard first-line treatment.
Read More
NFBISI-18 Questionnaire Provides QOL Insights in Urothelial Carcinoma
November 13th 2023An analysis, based on data from the JAVELIN 100 Bladder trial, found the NCCN/FACT Bladder Symptom Index-18 for assessing quality-of-life in patients with advanced urothelial carcinoma to be reliable and valid.
Read More